The key efficacy endpoint was transform from baseline MADRS rating. This shorter-time period review observed that, compared to intranasal placebo additionally oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant noticeably enhanced depressive symptoms after 4 weeks by a necessarily mean difference of four points abo